Skip to main content
Premium Trial:

Request an Annual Quote

Thermo Fisher Inks $500M Subscription Agreement to Fund Life Tech Purchase

NEW YORK (GenomeWeb News) – Thermo Fisher Scientific today said that it has entered into a subscription agreement to raise $500 million in gross proceeds to help fund its purchase of Life Technologies.

Under the terms of the agreement, which Thermo Fisher disclosed in a document filed with the US Securities and Exchange Commission, the company will issue in a private placement up to approximately 5.3 million shares of its common stock to Temasek at $95 per share. The share price will be adjusted depending on when the investment closes.

Temasek is a government-owned investment firm based in Singapore.

Thermo Fisher said it does not expect to sell any more equity or equity-linked securities to fund the $13.6 billion acquisition of Life Tech, expected to be completed in early 2014. It previously raised $2.2 billion in a public offering of its shares and entered into a bridge credit agreement and term loan agreement totaling $12.5 billion in order to finance the deal.

In Friday morning trade on the New York Stock Exchange, shares of Thermo Fisher were up 1 percent at $101.18.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more